<scp>HCV</scp>treatment rates and sustained viral response among people who inject drugs in seven<scp>UK</scp>sites: real world results and modelling of treatment impact
Natasha K. Martin(University of California San Diego), Matthew Hickman(Glasgow Caledonian University), Stephen Ryder(Nottingham University Hospitals NHS Trust), Vivian Hope(Liverpool John Moores University), John Dillon(Mayo Clinic), Noel Craine, Heide Busse(Leibniz Institute for Prevention Research and Epidemiology - BIPS), Daniela De Angelis(Central Intelligence Agency), Peter Vickerman(At Bristol), Sharon Hutchinson(Glasgow Caledonian University), Matthew Cramp(New York Academy of Medicine), M Lyons, Graham R. Foster(Queen Mary University of London), Mary Ramsay(University of the Witwatersrand), Amanda Clements(Plymouth Hospital), William L. Irving(University of Nottingham), David Goldberg(Health Protection Scotland), J. Vilar(Pennine Acute Hospitals NHS Trust), F. Gordon(University of Bristol), Andrew Ustianowski(North Manchester General Hospital)
Cited by 92
Related Papers
HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection
|Science|2004|1.2k
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
|Hepatology|1998|564
MAIT cells are activated during human viral infections
|Nature Communications|2016|520
Increase in primary liver cancer in the UK, 1979–94
|The Lancet|1997|506
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484